Cargando…
External Limiting Membrane Disruption Predicts Long-Term Outcome in Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular Degeneration
The use of anti-vascular-endothelial growth factor agents for neovascular age-related macular degeneration (nAMD) in different treatment schemes is widely common in clinical practice. However, there is currently limited data on the long-term outcomes of a strict treat-and-extend regimen (TER) and im...
Autores principales: | Hoffmann, Laura, Hatz, Katja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446694/ https://www.ncbi.nlm.nih.gov/pubmed/34540863 http://dx.doi.org/10.3389/fmed.2021.706084 |
Ejemplares similares
-
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
por: Ebneter, Andreas, et al.
Publicado: (2020) -
Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen
por: Hirata, Yuki, et al.
Publicado: (2022) -
Peripapillary and macular microvasculature in neovascular age-related macular degeneration in long-term and recently started anti-VEGF therapy versus healthy controls
por: Türksever, Cengiz, et al.
Publicado: (2023) -
One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022) -
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)